A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

NIH

Sponsor class

Conditions

Recurrent Langerhans Cell Histiocytosis
Refractory Langerhans Cell Histiocytosis

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography Test
PROCEDURE: FDG-Positron Emission Tomography and Computed Tomography Scan
PROCEDURE: Lumbar Puncture
PROCEDURE: Multigated Acquisition Scan
DRUG: Tovorafenib

Sponsor

National Cancer Institute (NCI)